Meloxicam Gp (Meloxicam)

Meloxicam inhibits the cyclooxygenase enzymes COX‑1 and COX‑2, with a preference for COX‑2. This inhibition blocks the conversion of arachidonic acid to prostaglandins, which are mediators of inflammation, pain and fever. By lowering prostaglandin levels, meloxicam reduces the inflammatory response at the site of injury.

The appropriate dose of meloxicam is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, renal and hepatic function, and other individual factors. Dosage regimens may vary, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for meloxicam during pregnancy and lactation are limited. Because NSAIDs can affect fetal cardiovascular development and may pass into breast milk, meloxicam is generally avoided unless the potential benefit outweighs the risk. Pregnant or nursing patients should discuss alternatives with their physician.

To place an order, submit an enquiry on the Meloxicam Gp product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meloxicam offers a longer half‑life and greater COX‑2 selectivity than many traditional NSAIDs, which can translate into once‑daily dosing and a potentially lower risk of gastrointestinal irritation. However, it shares class‑wide risks such as cardiovascular and renal effects, so individual patient factors guide the choice of NSAID.

Meloxicam Gp should be stored at ambient temperature below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in areas with high humidity or temperature fluctuations.

Meloxicam is administered orally, typically as a tablet or capsule that is swallowed whole with water. It can be taken with or without food, but taking it with food may help reduce mild gastrointestinal discomfort in some patients.

Serious risks include gastrointestinal ulceration or bleeding, hepatotoxicity (liver injury), renal impairment (acute kidney injury or worsening chronic kidney disease), severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and an increased risk of cardiovascular events like myocardial infarction or stroke, especially with long‑term use.

Meloxicam should be avoided in patients with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulcer disease, severe heart failure, uncontrolled hypertension, significant renal or hepatic impairment, and in those who are pregnant beyond the first trimester unless clearly indicated by a physician.